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The phosphodiesterase 4 inhibitor roflumilast prevents bleomycin- (BLM-) induced lung fibrosis in animal models. However, its
mechanism of action remains unknown. We investigated whether roflumilast N-oxide (RNO), the active metabolite of roflumilast,
canmodulate in vitro the oxidative effects of BLMonhuman lung fibroblasts (HLF). In addition, since BLM increases the production
of F
2
-isoprostanes that have per se fibrogenic activity, the effect of RNO on oxidative stress and fibrogenesis induced by the F
2
-
isoprostane 8-epi-PGF2𝛼 was investigated. HLF were preincubated either with the vehicle or with RNO and exposed to either BLM
or 8-epi-PGF2𝛼. Proliferation and collagen synthesis were assessed as [
3H]-thymidine and [3H]-proline incorporation. Reactive
oxygen species (ROS) and F
2
-isoprostanes were measured. NADPH oxidase 4 (NOX4) protein and mRNA were also evaluated.
BLM increased both cell proliferation and collagen synthesis and enhanced ROS and F
2
-isoprostane production.These effects were
significantly prevented by RNO. Also, RNO significantly reduced the increase in both NOX4mRNA and protein, induced by BLM.
Finally, 8-epi-PGF2𝛼 per se stimulated HLF proliferation, collagen synthesis, and NOX4 expression and ROS generation, and RNO
prevented these effects.Thus, the antifibrotic effect of RNO observed in vivomay be related to its ability to mitigate ROS generation
via downregulation of NOX4.
1. Introduction
Roflumilast is a selective phosphodiesterase 4 (PDE4) inhib-
itor approved for the treatment of severe chronic obstructive
pulmonary disease (COPD) [1]. In experimental animals,
roflumilast has been found to prevent cigarette smoke-
induced emphysema [2] which is consistent with its clinical
indication. However, it is of interest that in mice and rats
challengedwith the fibrogenic agent bleomycin (BLM), roflu-
milast was also found to reduce parameters of inflammation
as well as markers of fibrosis such as lung collagen content
and histologically assessed lung fibrosis [3]. Additionally, in
these animals, the accumulation of lipid hydroperoxides in
bronchoalveolar lavage fluid (BAL), a parameter of oxidative
burden, was also attenuated by roflumilast. It was postulated
that inhibition of either lung fibroblast function [4], the
early inflammatory response [3], or the oxidative burden [5]
induced by BLM may have contributed to the antifibrotic
effect of roflumilast in vivo.
The present study was carried out in vitro on cultured
human lung fibroblasts (HLF) to investigate a potential direct
effect of roflumilast N-oxide (RNO), the active metabolite
of roflumilast [6], on oxidative stress burden and fibrogenic
effects induced by BLM.
Nicotinamide adenine dinucleotide phosphate oxidase 4
(NOX4) has been recognized as a major source of reactive
oxygen species (ROS) and has recently been implicated in
the fibrogenic response to lung injury [7, 8]. Lung fibrob-
lasts from patients with idiopathic pulmonary fibrosis (IPF)
express higher levels of NOX4 mRNA [9], and NOX4 siRNA
has been found to mitigate the fibrotic response in BLM-
treated mice [10]. Also, small molecule inhibitors of NOX4
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have recently been reported to be effective in the BLM
model [11]. RNO and other PDE4 inhibitors have previously
been reported to significantly inhibit ROS production under
experimental conditions [6], but no information is available
on the effect of RNO on NOX4.
In addition, BLM was found to increase in vivo the
production of F
2
-isoprostanes [12], the most proximal prod-
ucts of lipid peroxidation, which have been found to have
fibrogenic activity per se [13, 14]. This suggests that F
2
-
isoprostanes are not merely markers of oxidative stress but
may also contribute to the pathogenesis of this condition.
Thus, the effect of RNO on oxidative stress and markers of
a fibrogenic process induced by the F
2
-isoprostane 8-epi-
PGF
2𝛼
was also investigated.
2. Materials and Methods
2.1. HLF Treatment with BLM, 8-epi-PGF
2𝛼
, and Roflumilast
N-Oxide. Three different normal HLF (C-12360) were pur-
chased from PromoCell GmbH (Heidelberg, Germany) and
were originally obtained by never smokers donors. Selected
experiments compared all three different HLF isolates. Cells
were used between passages four and seven, seeded at a
density of 6 × 104 cells/mL in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), and allowed to grow to confluence. Twenty-
four hours before the treatment, the medium was changed
to serum-free DMEM. Cells were preincubated for 30min
with vehicle (0.1% dimethyl sulfoxide) or RNO (Nycomed
GmbH, Konstanz, Germany). RNO was used at 2 nM, cor-
responding to therapeutic plasma levels [15]. Cells were
then treated with either BLM (Bleomycin Sulphate Nippon
Kayaku, Sanofi Aventis) at 0.1–100mU/mL or 8-epi-PGF
2𝛼
(BIOMOL Research Laboratories Inc., USA) in the range of
concentrations 10−10–10−7M previously detected in in vivo
experiments [16]. A stock solution of 8-epi-PGF
2𝛼
(1mg/mL
in ethanol) was diluted to a concentration of 10−5M and
then further diluted to final concentrations with DMEM.
Cytotoxicity was assessed by lactate dehydrogenase (LDH)
Kit (DASIT S.p.A., Cornaredo, MI, Italy).
2.2. DNA Synthesis. Cell proliferation was evaluated in 24-
well plates by measuring [3H]-thymidine incorporation,
according to Boscoboinik et al. [17]. Subconfluent cells were
incubated with either BLM or 8-epi-PGF
2𝛼
for 24 h in serum-
free DMEM, in presence or absence of RNO. Six hours before
the measurements, 10 𝜇Ci/mL of [3H]-thymidine was added.
Cell layers were then washed, fixed for 20min with ice-cold
5% trichloroacetic acid (TCA), and solubilized in 0.4mL of
0.1M NaOH/2% Na
2
CO
3
. Samples were mixed with 8mL
of Ultima Gold (Packard) and counted for radioactivity in a
Packard 2100 TriCarb liquid scintillation analyser. Results are
expressed as [3H]-thymidine incorporation (dpm) per well.
2.3. Collagen Synthesis Assay. To evaluate the effect of BLM
or 8-epi-PGF
2𝛼
on collagen metabolism, HLF were seeded
on 12-well plates and grown to visual confluence. Medium
was changed to serum-free DMEM for 24 h to allow the
cells to become relatively quiescent. In addition to DMEM,
11.5 𝜇g/mL L-proline, and 50𝜇g/mL ascorbic acid, 50𝜇g/mL
𝛽-aminopropionitrile were added. After incubation, cells
were treated either with BLM or 8-epi-PGF
2𝛼
with or without
RNO for 48 h. Collagen synthesis was assessed as previously
reported [16]. Briefly, 16 h before the end of the 48 h treat-
ment, 10 𝜇Ci/mL of [3H]-proline (Amersham International;
specific activity 23 Ci/mmol) was added to each well. Media
were harvested for determination of [3H]-proline incor-
poration into collagen and noncollagen proteins following
the collagenase digestion method, by using highly purified
bacterial collagenase (Calbiochem Cat. no. 234134, 250 IU).
Incorporation of radioactivity into collagen and noncolla-
gen proteins was determined following precipitation with
TCA. Collagen-incorporated radioactivity was recovered in
the TCA-soluble fraction, while noncollagen radioactivity
was recovered from TCA precipitate. Percentage collagen
synthesis was estimated as previously reported [18].
2.4. ROS Production. ROS levels were measured using
the 2󸀠,7󸀠-dichlorodihydrofluorescein diacetate (H
2
DCFDA)
probe as previously reported [19]. Prior to the experiments,
cells were incubated in media containing 1% FBS, preincu-
bated 30min in presence or absence of RNO, and then treated
with either BLM or 8-epi-PGF
2𝛼
for the indicated times.
After washing, HLF were returned to Dulbecco’s phosphate
buffered saline (D-PBS) and loaded with 10 𝜇M H
2
DCFDA
in D-PBS for 15min at 37∘C. Changes in fluorescence were
measured by a Perkin-Elmer fluorescence plate reader.
2.5. Determination of 8-epi-PGF
2𝛼
Levels. HLF were seeded
in T75 flasks (6 × 106 cells/flask) and 8-epi-PGF
2𝛼
levels
determined by enzyme immunoassay (Cayman Chemical,
AnnArbor,MI). F
2
-isoprostane levels are expressed as pg/106
cells.
In order to investigate if NOX activity is involved in
8-epi-PGF
2𝛼
production, HLF were treated for 1 h with
1 𝜇M diphenyleneiodonium chloride (DPI) (Sigma-Aldrich),
an NADPH oxidase inhibitor, before stimulation with
50mU/mL BLM for 24 h, and then isoprostane levels were
determined as described above.
2.6. NOX4 Expression in HLF. Protein lysates were col-
lected, and Western blot analysis for NOX4 was performed
using rabbit anti-human primary antibodies for NOX4
(1 : 1000, Novus Biologicals, Littleton, CO,USA) as previously
described [20]. NOX4 mRNA expression was quantified by
quantitative real-time RT-PCR by use of the PCR ABI Prism
7700 Sequence Detector (Perkin Elmer Applied Biosystems).
Primers were synthesized using Primer Express version 1.0
software (PerkinElmer Applied Biosystems) according to the
published cDNA sequences for NOX4 and 𝛽-actin as internal
control.
2.7. Statistical Analyses. Each experiment was carried out
a minimum of three times, and statistical analyses were
performed. Bartlett’s test was used to verify the equality
of variance. Nonparametric Kruskal-Wallis test followed
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by Dunn’s post-test was performed on data with unequal
variances. When appropriate, one-way ANOVA and Tukey’s
post-test were used. A significant effect was indicated by a
𝑃 value < 0.05. All data are presented as the mean ± SD
for 3 independent experiments, each performed at least in
triplicate.
3. Results
3.1. Effect of BLM on LDH Release fromHLF. Bleomycin may
trigger cytotoxicity and therefore LDH release fromHLF was
measured. Cells were treated for 24 h with BLM in the range
of concentrations 0.1–100mU/mL, as reported in Section 2. A
significant increase in LDH release was observed only at the
concentration of 100mU/mL (data not shown). Thus, in the
following studies, concentrations of BLM ≤50mU/mL were
used.
3.2. RNOCurbs BLM-Induced HLF Proliferation and Collagen
Synthesis. To evaluate the effect of RNO on the fibrogenic
effects of BLM, HLF were preincubated with the PDE4
inhibitor and stimulated with 50mU/mL of BLM. The addi-
tion of BLM-induced a significant increase in cell prolifer-
ation and collagen synthesis. [3H]-thymidine incorporation
was increased by 1.6-fold (Figure 1(a)), while the relative col-
lagen production, measured as percentage collagen synthesis
over total protein synthesis, was increased by about 1.8-fold
(Figure 1(b)). In unstimulated cells, RNO did not influence
both parameters. However, when stimulated with BLM, RNO
abolished the BLM-induced DNA and collagen synthesis in
HLF (Figures 1(a) and 1(b)).
3.3. Effect RNO on Oxidative Stress Levels in HLF Treated with
BLM. To assess whether the reduced fibrogenic response
(DNA and collagen synthesis) to BLM by RNO may be
related to a decrease in oxidative burden, ROS release
and generation of F
2
-isoprostanes were evaluated. For ROS
determination, HLF were incubated for 4 and 24 h with
BLM (0.1–50mU/mL). An increased response was observed
at both time intervals (Figure 2(a)). The effect of RNO on
BLM-induced ROS release was evaluated after 24 h in HLF
treated with or without 50mU/mL BLM. In the absence
of BLM, RNO did not affect ROS production. On the
other hand, when stimulated with BLM, RNO reduced this
increment by 87% (Figure 2(b)). The burden of oxidative
stress was also evaluated as release of F
2
-isoprostanes. A 3-
fold increase in 8-epi-PGF
2𝛼
production was observed in
HLF treated with BLM (Figure 3). Pre-incubation with RNO
abolished the BLM-induced F
2
-isoprostane increase. Fur-
thermore, the presence of DPI (a broad spectrum NADPH
oxidase inhibitor) strongly reduced the BLM-induced F
2
-
isoprostane release in HLF (Figure 4).
3.4. Effect of BLM and RNO on NOX4 Expression in HLF.
A critical role of NOX4 in lung fibroblast ROS generation
and fibrogenic signaling has been described, and NOX4 is
increased in IPF lung fibroblasts [21]. Therefore, the effects
of BLM and RNO on NOX4 expression were evaluated in
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Figure 1: Effect of BLMandRNOonHLF proliferation and collagen
synthesis. HLF were preincubated or not with RNO (2 nM) for
30min and then treated with BLM (50mU/mL). (a) Cell prolifera-
tion was evaluated on HLF from three different donors after 24 h by
measuring [3H]-thymidine incorporation. Results are expressed as
[3H]-thymidine incorporation (dpm) per well. Each sample was run
in quadruplicate. Data are mean ± SD of 3 experiments. ∗𝑃 < 0.05
versus control (C); #𝑃 < 0.05 versus BLM. (b) For determination of
[3H]-proline incorporation into collagen and noncollagen proteins,
media were harvested after 48 h of treatment. Results are presented
as percentage of untreated control. Data are mean ± SD of 3
experiments each in quadruplicate. ∗𝑃 < 0.05 versus control (C);
#
𝑃 < 0.05 versus BLM.
HLF after an incubation period of 24 h. Immunoblot analysis
revealed that BLM-induced about 3-fold increase in NOX4
protein (Figures 5(a) and 5(b)). No effect was seen with RNO
in the absence of BLM. Pre-incubation with RNO prevented
the NOX4 increase induced by BLM. A similar trend was
observed for NOX4 mRNA expression (Figure 5(c)).
3.5. Effect of 8-epi-PGF
2𝛼
on LDH Release by HLF. The cyto-
toxicity of various 8-epi-PGF
2𝛼
concentrations was assessed
bymeans of LDHrelease inHLF.After 24 h, a significant LDH
release was observed only with the 10−7M concentration
(data not shown).
3.6. Effect of 8-epi-PGF
2𝛼
and RNO on ROS Production and
NOX4 Expression by HLF. 8-epi-PGF
2𝛼
induced an increase
in ROS levels that peaked at 10−8M (1.3-fold, 𝑃 < 0.05)
following a 24 h incubation time. The increase in ROS
4 Mediators of Inflammation
0
2000
4000
6000
8000
10000
12000
14000
C 0.1 1 10 50 
BLM (mU/mL)
RO
S 
flu
or
es
ce
nc
e (
a.u
.)
∗
∗∗∗
(a)
RO
S 
flu
or
es
ce
nc
e (
a.u
.)
0
4000
8000
12000
16000
C BLM RNO
###
BLM + RNO
∗
∗∗∗
(b)
Figure 2: BLM-induced oxidative stress in HLF. (a) HLF were
treated with various concentrations of BLM, and the generation of
ROS was evaluated at 4 (white bar) and 24 (black bar) h. ROS levels
were measured using the probe 2󸀠,7󸀠-dichlorodihydrofluorescein
diacetate (H
2
DCFDA). ROS production was determined over a
60min period. (b) The effect of RNO on the formation of ROS was
evaluated in HLF from 3 different cell lines preincubated for 30min
in presence or absence of RNO (2 nM) and then treated with BLM
(50mU/mL) for 24 h. The results are expressed as arbitrary units
of fluorescence measured on a PerkinElmer Applied Biosystems
fluorescence plate reader (excitation 490 nm; emission 535 nm).
Data are mean ± SD of 3 experiments. ∗𝑃 < 0.05 versus control
(C); ∗∗∗𝑃 < 0.001 versus control (C); ###𝑃 < 0.001 versus BLM.
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Figure 3: Effect of BLM and RNO on 8-epi-PGF
2𝛼
release in HLF.
Levels of F
2
-isoprostanes (8-epi-PGF
2𝛼
) were determined by an
enzyme immunoassay kit in themedia ofHLF from 3 donors treated
with BLM (50mU/mL) for 24 h, in presence or absence of RNO
(2 nM). Data are mean ± SD of 3 experiments. ∗∗𝑃 < 0.001 versus
control (C); #𝑃 < 0.05 versus BLM.
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Figure 4: Involvement of NOX activity in BLM-induced 8-epi-
PGF
2𝛼
release. Levels of F
2
-isoprostanes (8-epi-PGF
2𝛼
) were deter-
mined in the media of HLF from 3 donors treated with BLM
(50mU/mL) for 24 h, in presence or absence of DPI (1𝜇M), a
broad NOX activity inhibitor. Data are mean ± SD of 3 separate
experiments, each performed in triplicate. ∗𝑃 < 0.05 versus control
(C); ∗∗𝑃 < 0.01 versus control (C); ##𝑃 < 0.01 versus BLM.
observed with a concentration of 10−7M was lower than that
observed with a concentration of 10−8M likely caused by
cytotoxicity (Figure 6(a)). Thus, 8-epi-PGE
2𝛼
at 10−8M has
been used in the following studies. RNO did not change ROS
levels in resting HLF. On the other hand, pre-incubation with
RNO significantly reduced the increase in ROS induced by
8-epi-PGF
2𝛼
(Figure 6(b)).
Moreover, an increased expression of NOX4 was ob-
served inHLF treatedwith 8-epi-PGE2
𝛼
for 24 h (Figures 7(a)
and 7(b)), and this effect was prevented by the pre-incubation
with RNO.
3.7. Effect of 8-epi-PGF
2𝛼
and RNO on HLF Proliferation and
Collagen Synthesis. 8-epi-PGF
2𝛼
(10−8M) significantly en-
hanced DNA synthesis. RNO abolished this 8-epi-PGF
2𝛼
-
induced increase in [3H]-thymidine incorporation inHLF. In
the absence of 8-epi-PGF
2𝛼
, RNO did not affect HLF prolif-
eration (Figure 8(a)). 8-epi-PGF
2𝛼
also induced a moderate
but significant increase in HLF collagen synthesis assessed as
[3H]-proline incorporation after 48 h of incubation. In these
experiments, the relative collagen production, measured as
percentage collagen synthesis over total protein synthesis
(collagenic plus noncollagenic proteins), was increased by
about 1.3-fold. At baseline, RNO did not affect collagen pro-
duction. However, when stimulated with 8-epi-PGF
2𝛼
, pre-
incubation with RNO prevented the 8-epi-PGF
2𝛼
-induced
collagen synthesis in HLF (Figure 8(b)).
4. Discussion
The main point of this study consists in the finding that
the PDE4 inhibitor RNO prevented the oxidative stress
induced by the fibrogenic agent BLM in HLF, and this
was accompanied by a reduction of BLM-induced fibroblast
proliferation and collagen release. In fact, RNO inhibited
the BLM-induced ROS and F
2
-isoprostane production and
abolished the increase in expression of NOX4 induced by
BLM.
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Figure 5: Effect of BLM and RNO on NOX4 expression in HLF. (a) Cells were preincubated or not with RNO (2 nM) and then treated for
24 h with BLM (50mU/mL). Protein expression of NOX4 was analyzed by Western blotting. (b) Quantification of proteins was expressed as
a ratio to 𝛽-actin. Data are mean ± SD of 3 experiments. ∗∗𝑃 < 0.01 versus control (C); ##𝑃 < 0.01 versus BLM. (c) NOX4 gene expression
in HLF was evaluated by real-time PCR. The isolated mRNA samples were analyzed using the specific primers and compared with 𝛽-actin
(housekeeping gene) levels. Data are mean ± SD of 3 experiments. ∗𝑃 < 0.05 versus control (C); #𝑃 < 0.05 versus BLM.
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Figure 6: Effect of 8-epi-PGF
2𝛼
(ISO) and RNO on ROS production by HLF. (a) HLF were treated for 24 h with various concentrations of
8-epi-PGF
2𝛼
. ROS levels were measured as described in Section 2.4. ROS production was determined over a 60min period. (b) Cells were
preincubated for 30min in presence or absence of RNO (2 nM) and then treated with 8-epi-PGF
2𝛼
(10−8M) for 24 h.The results are expressed
as arbitrary units of fluorescence. Data are mean ± SD of 3 experiments. ∗𝑃 < 0.05 versus control (C); #𝑃 < 0.05 versus 8-epi-PGF2𝛼.
Recent studies indicate that NOX4 plays a role in the
signaling pathways involved in pulmonary fibrosis patho-
physiology [10, 21]. Stimulation of NOX4 expression was
accompanied by an increase in ROS production [9]. Further-
more, NOX4-dependent production of H
2
O
2
was required
for myofibroblast differentiation and extracellular matrix
production [10]. In an interesting in vivo study, BLM was
administered to mice deficient in the p47phox subunit of the
NADPH oxidase complex. In this study, phorbol 12-myristate
13-acetate stimulation of BAL cells from KO mice produced
no detectable ROS, while BAL cells from wild type mice did.
In addition, hydroxyproline assays in the lung tissue at 14 days
after BLM administration revealed the absence of collagen
deposition in the lungs of the KO mice in contrast to wild
type mice.The authors concluded that these findings provide
strong evidence for cellular ROS production as an important
component of the fibrogenic environment [22].
In the present study, BLM was found to increase NOX4
mRNA and protein expression and RNO was able to prevent
this effect. To our knowledge, this is the first demonstration
that RNO can modulate NOX4. Furthermore, we observed
that BLM-induced amarked increase in 8-epi-PGF
2𝛼
produc-
tion in HLF. It has been previously reported that 8-epi-PGF
2𝛼
induces NOX4 [23]. Accordingly, our data demonstrate that
8-epi-PGF
2𝛼
increased the formation of ROS and upregulated
NOX4 expression inHLF.Thepresence of a broad inhibitor of
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Figure 7: Effect of 8-epi-PGF
2𝛼
and RNO on NOX4 expression in HLF. Cells from 3 separate donors were preincubated or not with
RNO (2 nM) and then treated for 24 h with 8-epi-PGF
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(10−8M). (a) Protein expression of NOX4 was analyzed by Western blotting. (b)
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versus BLM.
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Figure 8: Effect of 8-epi-PGF
2𝛼
(ISO) and RNO on HLF proliferation and collagen synthesis. (a) Cells were preincubated for 30min in
presence or absence of RNO (2 nM) and then stimulated with 8-epi-PGF
2𝛼
(10−8M). Cell proliferation was evaluated after 24 h by measuring
[3H]-thymidine incorporation in HLF. Results are expressed as [3H]-thymidine incorporation (dpm) per well. Each sample was run in
quadruplicate. Data are mean ± SD of 3 experiments. ∗∗𝑃 < 0.01 versus control (C); ##𝑃 < 0.01 versus 8-epi-PGF2𝛼 (ISO). (b) Media
were harvested after 48 h of treatment for determination of [3H]-proline incorporation into collagen and noncollagen proteins. Results
(collagen/total protein) are presented as percentage of untreated control. Data are mean ± SD of 3 experiments. ∗𝑃 < 0.05 versus control (C);
#
𝑃 < 0.05 versus 8-epi-PGF2𝛼 (ISO).
NOX activity (DPI) decreased the BLM-induced isoprostane
release in these cells.
Since in the present study RNO prevented both the BLM-
and 8-epi-PGF
2𝛼
-induced ROS production, it is suggested
that this effect may be, at least in part, attributed to the
inhibitory effect of RNO on NOX4.
In addition, in the current study, RNO inhibited BLM-
and 8-epi-PGF
2𝛼
-induced HLF proliferation and prevented
the increase in HLF collagen synthesis induced by both
BLM and 8-epi-PGF
2𝛼
. Fibroblast proliferation and collagen
synthesis are considered to play a pivotal role in the devel-
opment of fibrosis. RNO has previously been reported to
partially reduce [3H]-thymidine incorporation secondary to
basic fibroblast growth factor in HLF [4]. It is conceivable
that in our study the prevention by RNO of these BLM
and 8-epi-PGF
2𝛼
effects may rest, at least in part, on its
inhibition of ROS production by these two agents. It has been
suggested that cAMP, or more specifically PDE4 inhibitors,
can reduce ROS generation in human fibroblasts. Kokot et al.
[24] demonstrated that the treatment with cAMP inducers
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suppressed BLM-induced expression of collagen I and III in
human dermal fibroblasts.
F
2
-isoprostanes are considered as reliable markers of
oxidative stress [25].There is broad evidence that F
2
-isopros-
tanes are augmented in experimental animals after instilla-
tion of BLM [5, 12], indicating systemic oxidative stress.
Recently, F
2
-isoprostanes have also been reported to trigger
a fibrotic response. For example, in the liver, F
2
-isoprostanes
were found to increase collagen deposition and cellular
proliferation [13, 14].These effects involve a modified form of
isoprostane receptor, homologous to the classic thromboxane
A2-binding receptor [14]. It was this fibrogenic activity of
the F
2
-isoprostanes that prompted us to analyze the effect of
RNO on 8-epi-PGF
2𝛼
-stimulated HLF in the present study.
While the fibrogenic response was confirmed in HLF, as an
additional effect it was observed that 8-epi-PGF
2𝛼
increased
both ROS production and NOX4 expression in these cells.
5. Conclusions
The results of the present study demonstrate that RNO
had a powerful effect in preventing collagen deposition and
fibroblast proliferation induced by both BLM and 8-epi-
PGF
2𝛼
. This was accompanied by an inhibitory effect on the
expression of NOX4 and on the production of ROS and F
2
-
isoprostanes.
In the context of previous reports, these findings may
support the concept that the inhibition of the fibrogenic
process may be related to the ability of the PDE4 inhibitor to
mitigate cellular ROS generation. Further, these results may
provide a rationale for the reduction of BLM-induced lung
fibrosis by roflumilast in vivo in animal models.
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